MissionIR Articles
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Technology Revolutionizes CBD Delivery
Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the bloodstream, which results in increased absorption. A recent article discussing LXRP reads, “Its proprietary technology promises multiple…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Talks DehydraTECH’s Lifesaving Technology on CEO Clips
LXRP CEO Chris Bunka explained in the interview that proprietary technology can save 60,000 lives annually if consumption habits of even one percent of smokers worldwide change CEO Clips videos are featured on business sites…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches Its Largest Cannabinoid Research Program
The R&D program will focus on the proprietary Lexaria DehydraTECH delivery technology with the purpose of enhancing it further Results could contribute to new patent filings in the future; in addition, the program will examine…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Utilizes Disruptive Technology for Improved Delivery of Bioactive Compounds
Biotechnology company and drug-delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) utilizes disruptive technology for the improved delivery of bioactive compounds. A recent article discussing this reads, “Lexaria’s technology has been shown to be…
-
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Revolutionary Technology is Disrupting the Cannabis Edibles Industry
Lexaria Bioscience Corp. is the only company worldwide with patents issued for oral delivery of all cannabinoids Its proprietary technology bests traditional methods such as inhalation in several key ways The company continues to enhance…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Launches its Largest Cannabinoid R&D Program
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. According to…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Conduct Further Human Clinical Trials Following Positive TurboCBD Results
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) plans to conduct additional clinical trials using DehydraTECH(TM) in CBD after recently reporting noteworthy results of cardiovascular performance improvements with TurboCBD. A recent article discussing the company reads, “TurboCBD…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Innovating on Numerous Fronts with DehydraTECH Drug Delivery Platform
Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods Its DehydraTECH technology has…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Conduct Clinical Studies on Oral Nicotine Delivery Utilizing DehydraTECH Absorption Platform
Lexaria Nicotine LLC, a subsidiary of Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), recently secured research and development (“R&D”) funding in exchange for equity and licensing rights. Utilizing its DehydraTECH absorption platform, Lexaria will execute a…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Supports Recent FDA Statement on Novel Nicotine Replacement Therapies
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support for the Food & Drug Administration’s (“FDA”) February 21 statement titled “Smoking Cessation and Related Indications: Developing…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans Additional Clinical Trials Following Successful Tests
Company recently announced significant findings of cardiovascular performance improvements with TurboCBD Lexaria plans additional human clinical trials of CBD Company is now moving forward with clinical studies on oral forms of nicotine delivery following a…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Releases Additional Significant Findings of its DehydraTECH(TM) Powered TurboCBD(TM) Capsules
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional significant findings of TurboCBD(TM), the company’s proprietary, DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon completion of further data…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiaries Work to Secure New Deals for DehydraTECH in Various Industries
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is finding success through its ability to form subsidiaries specializing in the use of its patented drug-delivery platform, DehydraTECH. A recent article discussing the company reads, “DehydraTECH is a…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH
LXRP’s DehydraTECH research funded by a partner that will provide $1 million, with an option for millions more LXRP subsidiary Lexaria Nicotine LLC recently entered a definitive investment agreement to receive R&D funding in exchange…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry
Big corporations are investing in the cannabis industry Major tobacco company provides financing for LXRP LXRP boasts revenue streams within the nicotine industry and opportunity in other sectors Lexaria is a unique company doing business…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Secures Key R&D Funding for Oral Nicotine Delivery Using DehydraTECH Technology
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) wholly owned subsidiary, Lexaria Nicotine LLC, recently struck a deal with a large tobacco partner, securing significant R&D financing for the company’s DehydraTECH absorption platform (http://ibn.fm/Kx7Cm). A recent article…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Seeks to Improve Lives through Revolutionary Nicotine Delivery Method
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has joined forces with one of the world’s largest tobacco companies to fund the research and development of Lexaria’s…
-
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Receives New R&D Funding for Oral Nicotine Delivery Technology
LXRP subsidiary Lexaria Nicotine LLC enters definitive investment agreement with large tobacco company to receive R&D funding in exchange for licensing and equity Partner has provided initial $1 million – with an option for up…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery
Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Acquires a $12 Million Investor
Lexaria Nicotine LLC partners with one of the world’s largest tobacco companies Opportunity to change nicotine delivery and improve the lives of millions Retains ownership of DehydraTECH while licensing the technology out to multiple industries…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial